Stock Ratings / Health Care / QCLS / insiders

CDIO (31) TRIB (56) VRAX (58) BMRA (39) ⌘ Pro Terminal →

Q/C Technologies Inc. (QCLS) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Q: Are QCLS insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies QCLS leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

$0.44 -3.44% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.44

Q/C Technologies Inc. (QCLS) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $3.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.44 (-0.81%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-6.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for QCLS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (42/100 Composite)

🔍 WHY QCLS SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (29% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$0.63-14.3% Next Q

Q2 (-2Q)

Grade D$0.54-13% Next Q

Q3 (-1Q)

Grade D$0.47-6.4% Next Q

Current

Grade D-$0.44-7% Hist 90D α

Trajectory: C- (50) → D- (42)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a QCLS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While QCLS currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.09) and Max Pain ($0.46) forces dealer call-delta covering toward $8.58.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $QCLS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “QCLS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 42%NO 58%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

QCLS Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (QCLS)

No recent open-market Form 4 cluster sales or emergency dumps flagged on QCLS. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring QCLS)

✓Walkthrough of QCLS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

QCLS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -88.27%▼ DESCENDING CHANNEL

2026-10-30O $0.44H $0.46L $0.42C $0.44VOL 317.7K

RES: $0.91SUP: $-1.48SMA50: $1.09SMA200: $3.07

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

QCLS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 QCLS Butterfly Map → + Track QCLS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on QCLS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for QCLS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for QCLS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (QCLS)

Health Care Rank #600 of 1016 ⚔️ CDIO vs QCLS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (QCLS vs. CDIO, TRIB, VRAX, BMRA)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Q/C Technologies Inc. (QCLS) ranks #600 by composite RQD confidence (42/100, grade D-) and #968 by equity capitalization ($3.6M). Within this direct 5-issuer industry benchmark cohort, QCLS leads on earnings valuation at N/A trailing P/E, while QCLS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. VRAX currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with QCLS at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
QCLS ACTIVE Q/C Technologies Inc.	D-	42/100	—	—	-35.0%	-3.44%	$3.6M	Benchmark Subject
CDIO Cardio Diagnostics Holdings Inc.	E	31/100	—	—	-35.0%	+2.94%	$5.2M	/cdio-vs-qcls →
TRIB Trinity Biotech plc	D+	56/100	—	—	—	-2.50%	$5.4M	/trib-vs-qcls →
VRAX Virax Biolabs Group Limited	D+	58/100	—	—	—	+10.00%	$1.8M	/vrax-vs-qcls →
BMRA Biomerica Inc.	D-	39/100	—	8.1%	-35.0%	-0.57%	$8.0M	/bmra-vs-qcls →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001321834

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Q/C Technologies Inc. (QCLS) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$11.6M, operating cash flow of -$9.1M, and free cash flow of -$9.1M (-1.0% YoY). On the balance sheet, QCLS closed FY2025 with $41.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$11.6M	-$9.1M	-$9.1M	$41.2M	—
FY2024 (FY)	2024-12-31	$0	-$23.4M	-$9.0M	-$9.0M	$21.4M	—
FY2023 (FY)	2023-12-31	$0	-$4.0M	-$13.0M	-$13.0M	—	—

3. QCLS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is QCLS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Q/C Technologies Inc. (NASDAQ: QCLS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $0.44 (-3.44% 1D, market cap $3.6M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, QCLS ranks #600 in composite RQD confidence.

How does QCLS compare to CDIO and TRIB in the Health Care sector?

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), QCLS carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CDIO (Cardio Diagnostics Holdings Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $5.2M) and TRIB (Trinity Biotech plc) posts a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $5.4M). Among the 5-stock peer group, QCLS leads on earnings multiple (N/A) while QCLS leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for QCLS?

Per QCLS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001321834), Q/C Technologies Inc. generated $0 in revenue, -$11.6M in net income, and -$9.1M in free cash flow against $41.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is QCLS trading relative to its 50-day, 200-day, and 52-week technical levels?

QCLS last traded at $0.44 (-3.44% on volume of 113,491 shares), positioning the stock -59.63% below its 50-day simple moving average ($1.09) and -85.67% below its 200-day simple moving average ($3.07). Across its 52-week range of $0.42 to $8.17, QCLS sits at the 0.3% percentile with a 14-day RSI of 27.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.50).

QCLS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are QCLS insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies QCLS leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: QCLS RQD Cockpit QCLS 12M Forecast QCLS Earnings & Move QCLS Dividends & DRIP QCLS Insiders & 13F QCLS Whale Options QCLS Profit Sankey QCLS News & Why